Cargando…
Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs)
The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and curr...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635789/ https://www.ncbi.nlm.nih.gov/pubmed/29099030 http://dx.doi.org/10.3390/medsci5020014 |
_version_ | 1783270352835575808 |
---|---|
author | Renz, Bernhard W. D’Haese, Jan G. Werner, Jens Westphalen, C. Benedikt Ilmer, Matthias |
author_facet | Renz, Bernhard W. D’Haese, Jan G. Werner, Jens Westphalen, C. Benedikt Ilmer, Matthias |
author_sort | Renz, Bernhard W. |
collection | PubMed |
description | The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and current chemotherapeutic strategies only offer a modest improvement in overall survival. Accordingly, novel approaches are desperately needed. One hypothesis that could—at least in part—explain the desolate response of PDAC to chemotherapy is the so-called cancer stem cell (CSC) concept, which attributes specific traits, such as chemoresistance, metastatic potential and a distinct metabolism to a small cellular subpopulation of the whole tumor. At the same time, however, some of these attributes could make CSCs more permissive for novel therapeutic strategies with compounds that are already in clinical use. Most recently, several publications have tried to enlighten the field with the idea of repurposing established drugs for antineoplastic use. As such, recycling drugs could present an intriguing and fast-track method with new therapeutic paradigms in anti-cancer and anti-CSC treatments. Here, we aim to summarize important aspects and novel findings of this emerging field. |
format | Online Article Text |
id | pubmed-5635789 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2017 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-56357892017-10-26 Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) Renz, Bernhard W. D’Haese, Jan G. Werner, Jens Westphalen, C. Benedikt Ilmer, Matthias Med Sci (Basel) Review The diagnosis of pancreatic ductal adenocarcinoma (PDAC) carries a dismal prognosis, in particular, when patients present with unresectable disease. While significant progress has been made in understanding the biology of PDAC, this knowledge has not translated into a clear clinical benefit and current chemotherapeutic strategies only offer a modest improvement in overall survival. Accordingly, novel approaches are desperately needed. One hypothesis that could—at least in part—explain the desolate response of PDAC to chemotherapy is the so-called cancer stem cell (CSC) concept, which attributes specific traits, such as chemoresistance, metastatic potential and a distinct metabolism to a small cellular subpopulation of the whole tumor. At the same time, however, some of these attributes could make CSCs more permissive for novel therapeutic strategies with compounds that are already in clinical use. Most recently, several publications have tried to enlighten the field with the idea of repurposing established drugs for antineoplastic use. As such, recycling drugs could present an intriguing and fast-track method with new therapeutic paradigms in anti-cancer and anti-CSC treatments. Here, we aim to summarize important aspects and novel findings of this emerging field. MDPI 2017-06-19 /pmc/articles/PMC5635789/ /pubmed/29099030 http://dx.doi.org/10.3390/medsci5020014 Text en © 2017 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Renz, Bernhard W. D’Haese, Jan G. Werner, Jens Westphalen, C. Benedikt Ilmer, Matthias Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) |
title | Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) |
title_full | Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) |
title_fullStr | Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) |
title_full_unstemmed | Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) |
title_short | Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs) |
title_sort | repurposing established compounds to target pancreatic cancer stem cells (cscs) |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5635789/ https://www.ncbi.nlm.nih.gov/pubmed/29099030 http://dx.doi.org/10.3390/medsci5020014 |
work_keys_str_mv | AT renzbernhardw repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs AT dhaesejang repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs AT wernerjens repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs AT westphalencbenedikt repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs AT ilmermatthias repurposingestablishedcompoundstotargetpancreaticcancerstemcellscscs |